Residency · Residency · Respirology

Cystic Fibrosis in Adults - CFTR Modulators Era

Overview and Genetics

CFTR Gene and Protein

Cystic fibrosis is an autosomal recessive disorder caused by mutations in the CFTR gene, located on chromosome 7q31, which encodes a chloride and bicarbonate channel expressed on the apical surface of epithelial cells throughout the body. More than 2000 mutations have been identified in the CFTR gene, and these are classified into six classes based on the mechanism by which they disrupt normal protein function. Class I mutations, including G542X and W1282X, are nonsense or splice-site mutations that prevent any functional protein from being produced. Class II mutations cause protein misfolding and premature degradation in the endoplasmic reticulum; the most prevalent example is F508del, which accounts for approximately 70% of all CFTR alleles worldwide and is the most commonly encountered mutation in clinical practice. Class III mutations, exemplified by G551D, are gating defects in which the protein is correctly trafficked to the cell membrane but the channel fails to open properly. Class IV mutations, such as R117H, result in reduced conductance through an otherwise functional channel. Class V mutations involve splicing abnormalities that reduce the quantity of normal protein produced. Class VI mutations cause increased turnover of the protein at the cell surface, shortening its functional lifespan.

Epidemiology of Adult CF

The landscape of cystic fibrosis has changed dramatically over recent decades. The median predicted survival now exceeds 55 years according to the Cystic Fibrosis Foundation Patient Registry 2023, a figure that continues to rise rapidly as a direct consequence of CFTR modulator therapies. More than 50% of CF patients in many national registries are now adults, fundamentally shifting the demographic profile of the disease. An increasingly recognized population consists of adults diagnosed late in life, often with milder genotypes, atypical presentations, and partial CFTR function, who may present with recurrent sinopulmonary infections, isolated bronchiectasis, pancreatitis, or male infertility without having been identified during childhood.

Diagnosis in Adults

Diagnostic Criteria (CFF 2017)

The diagnosis of cystic fibrosis in adults requires clinical features consistent with the disease plus laboratory evidence of CFTR dysfunction. The sweat chloride test remains the cornerstone of diagnosis: a value of 60 mmol/L or greater is diagnostic, a value between 30 and 59 mmol/L falls in the intermediate range and warrants further testing, and a value below 30 mmol/L is normal and makes CF unlikely. Alternative confirmatory evidence includes identification of two disease-causing CFTR mutations in trans, or demonstration of abnormal CFTR function through nasal potential difference measurement or intestinal current measurement. The concept of CFTR-related disorder is applied to patients who present with clinical features in a single organ system and demonstrate CFTR dysfunction but do not meet the full diagnostic criteria for cystic fibrosis.

Late-Diagnosed Adults

Adults diagnosed with CF later in life often harbor milder genotypes, carrying at least one residual function mutation such as R117H or 3849+10kbC>T. Their clinical presentations tend to be more subtle, encompassing recurrent sinopulmonary infections, bronchiectasis, recurrent pancreatitis, male infertility due to congenital bilateral absence of the vas deferens (CBAVD), and nasal polyposis. A high index of clinical suspicion should be maintained for young adults presenting with so-called idiopathic bronchiectasis, particularly when sputum cultures yield Staphylococcus aureus or Pseudomonas aeruginosa, organisms that should always raise the question of underlying CF.

<image>A schematic diagram of the CFTR protein in the cell membrane showing its structure: two membrane-spanning domains (MSD1 and MSD2), two nucleotide-binding domains (NBD1 and NBD2), and the regulatory (R) domain. Map the six mutation classes onto the protein's journey from gene to cell surface: Class I (premature stop codon, no mRNA), Class II (misfolding in ER, proteasomal degradation - show F508del), Class III (protein at surface but channel closed - show G551D), Class IV (channel open but reduced ion flow), Class V (reduced mRNA, less protein), Class VI (accelerated turnover from surface). Use color coding for each class. Show chloride and bicarbonate ion movement through the open channel.</image>

CFTR Modulator Therapy

Classes of Modulators

CFTR modulator therapies are categorized by their mechanism of action at the molecular level. Potentiators improve channel gating by increasing the open probability of CFTR protein that has already reached the cell surface. Correctors improve the folding and intracellular trafficking of misfolded CFTR protein, enabling it to reach the cell membrane rather than being targeted for proteasomal degradation. Amplifiers, which remain investigational, increase CFTR mRNA transcription and thereby total protein production. Read-through agents, also investigational (with ELX-02 being the most advanced compound), promote ribosomal read-through of premature stop codons to restore production of full-length protein.

Ivacaftor (Kalydeco) - The First Potentiator

Ivacaftor was the first CFTR modulator approved for clinical use and functions as a potentiator that increases the channel open probability of CFTR protein already at the cell surface. Initially approved for patients carrying the G551D gating mutation (Class III), its label has expanded to encompass approximately 100 responsive mutations. The landmark STRIVE trial, conducted in patients aged 12 years and older with the G551D mutation, demonstrated an FEV1 improvement of 10.6 percentage points at 24 weeks, a 55% reduction in pulmonary exacerbations, and a remarkable sweat chloride reduction of approximately 48 mmol/L. The KONNECTION trial subsequently demonstrated efficacy in patients with the R117H residual function mutation. Ivacaftor is administered at 150 mg orally twice daily with fat-containing food, and side effects include headache, upper respiratory symptoms, and rash, with liver function tests recommended every 3 months during the first year of therapy.

Lumacaftor/Ivacaftor (Orkambi)

Lumacaftor/ivacaftor represented the first corrector-potentiator combination and was approved for patients homozygous for the F508del mutation. The TRAFFIC and TRANSPORT trials demonstrated a modest FEV1 improvement of 2.6-4.0 percentage points and a 30-39% reduction in exacerbation rate. The regimen is dosed as lumacaftor 400 mg combined with ivacaftor 250 mg taken orally every 12 hours. Significant limitations include substantial drug interactions arising from lumacaftor's potent CYP3A4 induction, which notably reduces the efficacy of hormonal contraceptives, chest tightness and dyspnea upon initiation, and ultimately a modest clinical benefit that has led to its replacement by elexacaftor/tezacaftor/ivacaftor in most clinical settings.

Tezacaftor/Ivacaftor (Symdeko/Symkevi)

Tezacaftor/ivacaftor represented the next-generation corrector-potentiator combination, offering improved tolerability and fewer drug interactions compared to lumacaftor/ivacaftor. The EVOLVE trial demonstrated an FEV1 improvement of 4.0 percentage points in F508del homozygous patients, while the EXPAND trial showed a 6.8 percentage point improvement in patients carrying F508del with a residual function mutation. Dosing consists of tezacaftor 100 mg with ivacaftor 150 mg taken once daily in the morning, plus an additional ivacaftor 150 mg dose in the evening. This combination has been largely superseded by the triple combination elexacaftor/tezacaftor/ivacaftor.

Elexacaftor/Tezacaftor/Ivacaftor (Trikafta/Kaftrio) - Transformative Therapy

Elexacaftor/tezacaftor/ivacaftor (ETI) represents the most transformative advance in cystic fibrosis therapeutics. This triple combination employs two correctors (elexacaftor and tezacaftor) working synergistically to improve CFTR folding and trafficking, combined with the potentiator ivacaftor to enhance channel gating at the cell surface. ETI is approved for patients aged 2 years and older carrying at least one F508del mutation, rendering approximately 90% of all CF patients eligible for this therapy. The pivotal VX-445-102 trial in F508del homozygous patients demonstrated an FEV1 improvement of 10.0 percentage points over tezacaftor/ivacaftor alone, a 63% reduction in exacerbations, and a massive reduction in sweat chloride. The VX-445-103 trial in patients carrying F508del with a minimal function mutation showed an even more striking FEV1 improvement of 14.3 percentage points over placebo, a 63% exacerbation reduction, and a sweat chloride reduction of 41.8 mmol/L. The VX-445-104 long-term extension study confirmed sustained FEV1 improvement at 96 or more weeks with durable exacerbation reduction. Dosing consists of elexacaftor 200 mg, tezacaftor 100 mg, and ivacaftor 150 mg taken together in the morning, with an additional ivacaftor 150 mg dose in the evening. Side effects include rash in 10-15% of patients, elevated liver function tests requiring monitoring every 3 months during the first year and annually thereafter, headache, diarrhea, and an initial increase in sputum production that paradoxically reflects improved mucus clearance. As a CYP3A4 substrate, dose reduction is required with moderate CYP3A4 inhibitors, strong inhibitors should be avoided, and dose adjustment is necessary in hepatic impairment.

Post-Modulator Clinical Changes

The dramatic efficacy of CFTR modulator therapy, particularly ETI, has introduced a new set of clinical considerations in the post-modulator era. Nutritional status improves substantially, with average weight gain of 3-5 kg in the first year, necessitating monitoring of BMI and emerging awareness of metabolic syndrome in a population historically characterized by underweight status. Fertility restoration in women requires urgent contraceptive counseling, as many CF women who previously had impaired fertility may become pregnant unexpectedly on modulator therapy. Mental health effects have emerged as a significant concern, with anxiety and depression sometimes manifesting or worsening as health improves, potentially related to survivor guilt, identity shifts, and the psychological adjustment to a fundamentally altered disease trajectory. Sputum production decreases substantially, and patients may need adjusted airway clearance regimens accordingly. CF-related diabetes may improve with CFTR correction but does not resolve, and screening must continue. Some centers have begun cautiously withdrawing chronic suppressive therapies such as azithromycin, inhaled antibiotics, and mucolytics in stable patients on ETI, though no consensus guidelines yet exist to guide this practice.

<image>A before-and-after comparison infographic showing the clinical impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy. Left side (pre-ETI): show typical CF parameters with poor values - FEV1 declining curve, frequent exacerbations (bar chart showing 2-3/year), elevated sweat chloride (>60 mmol/L), low BMI, thick mucus in airways (bronchial cross-section illustration). Right side (post-ETI): improved FEV1 trajectory (curve bending upward), reduced exacerbations (<1/year), normalized sweat chloride, improved BMI, thinner mucus with better ciliary clearance. Center: show the ETI molecule targeting CFTR at the cell surface. Include key trial data numbers from VX-445-102 and VX-445-103.</image>

Pulmonary Management Beyond Modulators

Chronic Infection Management

Chronic airway infection management remains a cornerstone of CF pulmonary care even in the modulator era. Staphylococcus aureus is the most common organism isolated in children, and anti-staphylococcal antibiotics are used for exacerbations, though the role of chronic prophylaxis remains controversial with divergent practices between the UK (favoring prophylaxis) and the US (not recommending routine prophylaxis). Pseudomonas aeruginosa chronically infects more than 60% of CF patients by age 25 in the pre-modulator era, and eradication is attempted upon first isolation using protocols such as TORPEDO-CF, which consists of 28 days of inhaled tobramycin with or without oral ciprofloxacin. Chronic Pseudomonas suppressive therapy options include inhaled tobramycin 300 mg twice daily on a 28-days-on, 28-days-off cycle, aztreonam lysine 75 mg three times daily on alternating months, and inhaled colistin. Methicillin-resistant Staphylococcus aureus (MRSA) is associated with worse clinical outcomes, and eradication protocols are under investigation with chronic suppressive therapy considered in some cases. Burkholderia cepacia complex infection, particularly with B. cenocepacia, is associated with rapid clinical decline and represents a relative contraindication to lung transplantation at some centers. Non-tuberculous mycobacterial infection, with Mycobacterium abscessus complex being the most problematic species, requires treatment according to ATS/IDSA guidelines.

Airway Clearance

Airway clearance remains a mandatory component of CF care regardless of modulator status. Dornase alfa (Pulmozyme), administered as 2.5 mg nebulized daily, cleaves extracellular DNA in purulent sputum and improves FEV1 by approximately 6%. Hypertonic saline at 7% concentration, nebulized twice daily, improves mucociliary clearance as confirmed by the CFSALT trial. Airway clearance techniques including positive expiratory pressure devices, the active cycle of breathing technique, chest physiotherapy, and regular exercise complement pharmacologic mucoactive therapy. In the post-ETI era, some patients with minimal sputum production may reduce but should not entirely eliminate airway clearance therapy.

Nutritional Management

Pancreatic enzyme replacement therapy (PERT) is titrated to control steatorrhea, with typical doses of 500-2500 lipase units per kilogram per meal. Fat-soluble vitamin supplementation with vitamins A, D, E, and K requires annual level monitoring. CF-related diabetes (CFRD) necessitates annual screening with oral glucose tolerance testing beginning at age 10, and insulin is the first-line treatment, as metformin alone is insufficient. An important clinical consideration is that HbA1c systematically underestimates glycemia in CF due to high red cell turnover, making OGTT the preferred screening standard rather than HbA1c. Post-modulator weight gain has introduced a transition from traditional underweight management to awareness of metabolic syndrome.

Complications and Monitoring

Pulmonary Complications

Hemoptysis ranges from minor episodes, which are frequent and usually managed conservatively, to massive hemoptysis exceeding 240 mL per 24 hours, which requires bronchial artery embolization and temporary cessation of airway clearance therapy. Pneumothorax occurs with an annual incidence of 3-4% and is managed with chest tube drainage and pleurodesis for recurrent episodes; importantly, pneumothorax is not an absolute contraindication to lung transplantation. Allergic bronchopulmonary aspergillosis (ABPA) has a prevalence of 5-15% in CF patients, complicates ongoing management, and is treated with corticosteroids and itraconazole. Progressive respiratory failure is an indication for transplant evaluation.

Extrapulmonary Monitoring

Liver disease requires annual liver function testing and ultrasonography for assessment of cirrhosis and portal hypertension, with ursodeoxycholic acid used for CF-related liver disease. Bone health screening with DEXA scanning should begin at age 18 and be repeated every 1-5 years, as osteoporosis and osteopenia are common in the CF population. Male infertility due to congenital bilateral absence of the vas deferens affects 97-98% of CF males, necessitating reproductive counseling and awareness of assisted reproduction options. Colorectal cancer screening should begin at age 40 given the increased risk, particularly in post-transplant patients. Mental health screening with annual PHQ-9 and GAD-7 assessments follows the International Committee on Mental Health guidelines.

Transition and Multidisciplinary Care

The transition from pediatric to adult CF care should follow a structured process ideally beginning at age 12-14, with formal transfer to an adult center at age 18-21. The multidisciplinary team essential to comprehensive CF care includes a respirologist, CF nurse specialist, physiotherapist, dietitian, social worker, psychologist, and pharmacist. Quarterly clinic visits should incorporate spirometry, sputum culture, weight measurement, and symptom review. An annual comprehensive review should include periodic HRCT, OGTT, liver function tests, fat-soluble vitamin levels, DEXA scanning, and mental health screening.

Key Clinical Pearls

• Elexacaftor/tezacaftor/ivacaftor (ETI) is eligible for ~90% of CF patients (those with at least one F508del allele) and has transformed the disease trajectory with sustained FEV1 improvement of 10-14% and > 60% exacerbation reduction
• Post-modulator era challenges include fertility restoration (urgent contraception counseling in women), metabolic syndrome with weight gain, and mental health impacts of a changing disease identity
• Dornase alfa (rhDNase) is beneficial in CF but HARMFUL in non-CF bronchiectasis - this distinction is critical and commonly tested
• CFRD requires insulin therapy; HbA1c systematically underestimates glycemia in CF due to high red cell turnover, and OGTT remains the screening standard
• Late-diagnosed adult CF should be suspected in young adults with "idiopathic" bronchiectasis, especially with Staphylococcus aureus or Pseudomonas colonization, nasal polyposis, or male infertility

References

1. Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819. (VX-445-103)
2. Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940-1948. (VX-445-102)
3. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672. (STRIVE)
4. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2023. Bethesda, MD: Cystic Fibrosis Foundation.
5. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808.

Read this lecture as Markdown